Biotechnology

120 Results

number of items to display at a time

Research

Jun 26, 2026

Compounding Asymmetries in Nucleic Acid Synthesis Screening: Policy Pathways for Strengthening Global Biosecurity Governance

This perspective argues that narrowing global screening asymmetries requires reframing adoption as a spectrum rather than an all-or-nothing compliance threshold.
Research

Jun 26, 2026

The Evolution of the United States Nucleic Acid Screening Policies

This review covers the evolution of nucleic acid synthesis screening guidelines, practices, and potential funding or regulatory requirements in the United States.
Research

Jun 25, 2026

Can LLM Agents Select and Engage with Biological Tools? An Initial Biosecurity Assessment

Large language model agents are capable of performing initial interactions with biological tools (BTs), indicating that agents could lower expertise barriers for actors seeking to use BTs. Targeted testing of agent design capabilities is warranted.
Expert Insights

Jun 15, 2026

Verifiable Audit Trails for AI-Enabled Biological Design Tools: A Proposal for Verifiable Biodesign Logging

The authors propose a tamper-evident audit-trail framework using cryptographic signing to establish a trustworthy chain of custody that can be used with any artificial intelligence–enabled biological design tool.
Project

Jun 1, 2026

Risk Index Observatory (RIO) for AI Biological Tools

The Risk Index Observatory is a continuously updated, automation-assisted platform for assessing the misuse capabilities of AI biological tools.
Expert Insights

May 20, 2026

Building Resilience Against Artificial Intelligence–Enabled Biological Threats: Conference Proceedings from a RAND and Helena Workshop

These conference proceedings summarize the outputs from a workshop in which participants developed broadly applicable mitigation strategies for possible threat scenarios at the intersection of artificial intelligence and biology.
Expert Insights

May 4, 2026

Open-Weight AI Models Require Proportional Evaluation Approaches

Open-weight AI models (OWMs) introduce distinct risk factors for which existing evaluation practices, largely designed for closed-weight model deployment, fail to account. The authors propose proportional evaluation approaches for OWMs.
Research

Apr 6, 2026

Infinite Potential—Insights from the Viral Uplift Scenario: After-Action Report from a Sequence of Day After Artificial General Intelligence Exercises

In this after-action report, the authors describe a series of exercises centered on the misuse of artificial intelligence models to generate novel biological threats and intended to elicit policy options that could help reduce the risks and impact.
Research

Mar 10, 2026

Cost–benefit analysis for synthetic nucleic acid screening in the European Union

An EU cost–benefit analysis of synthetic DNA/RNA screening policies comparing voluntary, conditional and mandatory approaches. Covers biosecurity risk reduction, market impacts, research effects and regulatory design implications for EU policymakers.
Commentary

Feb 27, 2026

Europe Is Betting on Biotech—But Success Depends on Demand

The success of the European Biotech Act should ultimately be judged on whether it meets health policy goals and whether patients across Europe can access, afford, and benefit from new therapies.
Research

Feb 11, 2026

Developing a Risk-Scoring Tool for Artificial Intelligence–Enabled Biological Design: A Method to Assess the Risks of Using Artificial Intelligence to Modify Select Viral Capabilities

A rise in artificial intelligence (AI) use in biology has driven transformative developments but could also pose dual-use risks. This report presents a multifaceted scoring system to assess the risks of using AI to modify select viral capabilities.
Expert Insights

Feb 10, 2026

Measuring Biological Capabilities and Risks of AI Agents: Generating and Interpreting Evidence from Agentic Evaluations

This perspective examines biological agentic evaluations as a tool for assessing risks from increasingly autonomous AI systems and offers practical guidance on how evaluation design shapes conclusions about biological capability and risk.

First
Previous
Page 2 of 10
Next
Last

Biotechnology

Biotechnology

Related Topics

Mirror Life Could Be Catastrophic. Here's How to Prevent It

Europe Is Betting on Biotech—But Success Depends on Demand

Explore RAND’s Work on this Topic

Error

Compounding Asymmetries in Nucleic Acid Synthesis Screening: Policy Pathways for Strengthening Global Biosecurity Governance

The Evolution of the United States Nucleic Acid Screening Policies

Can LLM Agents Select and Engage with Biological Tools? An Initial Biosecurity Assessment

Verifiable Audit Trails for AI-Enabled Biological Design Tools: A Proposal for Verifiable Biodesign Logging

Risk Index Observatory (RIO) for AI Biological Tools

Building Resilience Against Artificial Intelligence–Enabled Biological Threats: Conference Proceedings from a RAND and Helena Workshop

Open-Weight AI Models Require Proportional Evaluation Approaches

Infinite Potential—Insights from the Viral Uplift Scenario: After-Action Report from a Sequence of Day After Artificial General Intelligence Exercises

Cost–benefit analysis for synthetic nucleic acid screening in the European Union

Europe Is Betting on Biotech—But Success Depends on Demand

Developing a Risk-Scoring Tool for Artificial Intelligence–Enabled Biological Design: A Method to Assess the Risks of Using Artificial Intelligence to Modify Select Viral Capabilities

Measuring Biological Capabilities and Risks of AI Agents: Generating and Interpreting Evidence from Agentic Evaluations

Oops! An unexpected error has occurred.

RAND Headquarters

U.S. research divisions

International research divisions

Biotechnology

Biotechnology

Related Topics

Mirror Life Could Be Catastrophic. Here's How to Prevent It

Europe Is Betting on Biotech—But Success Depends on Demand

Explore RAND’s Work on this Topic

Error

Compounding Asymmetries in Nucleic Acid Synthesis Screening: Policy Pathways for Strengthening Global Biosecurity Governance

The Evolution of the United States Nucleic Acid Screening Policies

Can LLM Agents Select and Engage with Biological Tools? An Initial Biosecurity Assessment

Verifiable Audit Trails for AI-Enabled Biological Design Tools: A Proposal for Verifiable Biodesign Logging

Risk Index Observatory (RIO) for AI Biological Tools

Building Resilience Against Artificial Intelligence–Enabled Biological Threats: Conference Proceedings from a RAND and Helena Workshop

Open-Weight AI Models Require Proportional Evaluation Approaches

Infinite Potential—Insights from the Viral Uplift Scenario: After-Action Report from a Sequence of Day After Artificial General Intelligence Exercises

Cost–benefit analysis for synthetic nucleic acid screening in the European Union

Europe Is Betting on Biotech—But Success Depends on Demand

Developing a Risk-Scoring Tool for Artificial Intelligence–Enabled Biological Design: A Method to Assess the Risks of Using Artificial Intelligence to Modify Select Viral Capabilities

Measuring Biological Capabilities and Risks of AI Agents: Generating and Interpreting Evidence from Agentic Evaluations

Oops! An unexpected error has occurred.